Effect of short-term administration of cromakalim on renal hemodynamics and eicosanoid excretion in essential hypertension.
Cromakalim, a novel potassium channel-activating drug, was administered for a 3-day period in eight untreated hospitalized patients with established hypertension. The fixed and single dose of 1.5 mg/day produced a significant reduction in systolic and diastolic blood pressure with a small increase in heart rate. Glomerular filtration rate was unchanged and effective renal plasma flow was slightly increased with a concomitant small decrease in filtration fraction and in renal vascular resistance. No significant change was observed in urinary prostaglandin (PG)E2, PGF2 alpha, and thromboxane B2, while 6-keto-PGF1 alpha (the stable metabolite of prostacyclin) rose from 189 +/- 6 to 368 +/- 115 ng/day. The renal excretion of 6-keto-PGF1 alpha correlates with the modification observed in renal plasma flow, suggesting a compensatory role for prostacylin in preserving renal hemodynamics during antihypertensive therapy with cromakalim.
Lebel
M
M
L'Hôtel-Dieu de Québec, Canada.
Grose
J H
JH
Lacourcière
Y
Y
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000097:blood; D001578:Benzopyrans / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002712:Chlorides / Q000097:blood; D019806:Cromakalim; D015237:Dinoprost / Q000652:urine; D015232:Dinoprostone / Q000652:urine; D015777:Eicosanoids / Q000652:urine*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology / Q000652:urine*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011453:Prostaglandins / Q000652:urine; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D012964:Sodium / Q000097:blood; D013929:Thromboxane B2 / Q000652:urine; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology
D000959:Antihypertensive Agents; D001578:Benzopyrans; D002712:Chlorides; D015777:Eicosanoids; D011453:Prostaglandins; D011758:Pyrroles; D019806:Cromakalim; D013929:Thromboxane B2; D009320:Atrial Natriuretic Factor; D012964:Sodium; D015237:Dinoprost; D015232:Dinoprostone; D011188:Potassium